MedPath

Telehealth-Clinical Advocacy Project

Not Applicable
Completed
Conditions
Substance Use
Interventions
Behavioral: Telehealth
Registration Number
NCT04911426
Lead Sponsor
Texas Christian University
Brief Summary

The purpose of this study is to develop a clinical telehealth intervention and test the feasibility of integrating telehealth within a police opioid county diversion program.

Detailed Description

Participants in a police opioid diversion program will receive information about the research opportunity; those interested will be administered informed consent and randomized to either the (1) diversion program treatment as usual condition or (2) the enhanced condition, receiving the telehealth video call intervention with motivational interviewing and substance use treatment appointment reminders during the 12-week intervention. The study design has been modified to provide the enhanced condition with coaching and the T-CAP app to all individuals consented to the study beginning January 1, 2023.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8
Inclusion Criteria

Individuals interested in joining the study will be

  • Enrolled in the A Way Out Opioid Diversion Program (ODP),
  • At least 18 years of age,
  • Able to speak and understand English,
  • Have a history of opioid, alcohol, or other substance use within last 12 months,
  • Be willing to provide the research team with access to treatment records,
  • Have access to a phone, tablet or computer for the informed consent activity, and
  • Have a mailing address to receive a study phone issued to consented participants
Exclusion Criteria

Individuals not eligible for the study are

  • Not currently enrolled in the A Way Out Opioid Diversion Program on the day of consent,
  • Under the age of 18 on the day of consent,
  • Unable to speak and understand English,
  • Have a history of past opioid, alcohol, or other substance use longer than 12 months ago with no use of opioids in the last 12 months,
  • Unwilling to authorize the research team to access treatment records,
  • Without access to a phone, tablet or computer to complete the informed consent activity,
  • Without a mailing address

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Treatment plus telehealthTelehealthIndividuals will receive telehealth support services, including seven brief motivational interviewing sessions, delivered by a licensed substance use counselor via live interactive video calls during the 12-week intervention.
Primary Outcome Measures
NameTimeMethod
Percent of Participants Who Received One or More Referrals During the 12-week Intervention.12-week intervention period

The number of participants who received one or more referrals to services made by the intervention coach. This measure is collected as evidence supporting participant utilization of the app and the coaching support model.

Texas Christian University Drug Screen 5 Severity Score From Baseline to Post Intervention at Week 12Texas Christian University Drug Screen 5 data are reported for baseline and end-of-intervention at 12 weeks after consent.

The Texas Christian University Drug Screen 5 is a 19-question survey that captures substance use during the past 12 months. Interpretation of the TCU Drug Screen 5 score for drug use severity corresponds with the Diagnostic and Statistical Manual of Mental Disorders 5 criteria for reporting three possible severity levels (mild, moderate, severe). A single level score is based on participant responses to 11 items (total range: 0 to 11) as such: the presence of 2 to 3 endorsed symptoms is scored as a mild disorder; 4 to 5 endorsed symptoms is scored as moderate disorder; and a severe disorder is scored with the presence of 6 or more symptoms of the 11 items; thus, more endorsed items means a more serious drug use problem.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Lake County Public Health Department

🇺🇸

Waukegan, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath